Related references
Note: Only part of the references are listed.Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome A Randomized Clinical Trial
Ian Miller et al.
JAMA NEUROLOGY (2020)
Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial
Orrin Devinsky et al.
EPILEPSIA (2019)
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Elizabeth A. Thiele et al.
LANCET (2018)
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Orrin Devinsky et al.
NEUROLOGY (2018)
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Interactions between cannabidiol and commonly used antiepileptic drugs
Tyler E. Gaston et al.
EPILEPSIA (2017)
Long-term retention rates for antiepileptic drugs: A review of long-term extension studies and comparison with brivaracetam
Manuel Toledo et al.
EPILEPSY RESEARCH (2017)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Comparing Safety and Efficacy of Third-Generation Anti-epileptic Drugs: Long-Term Extension and Post-marketing Treatment
Charlotte S. Kwok et al.
CNS DRUGS (2017)
Mortality in Dravet syndrome
Monica S. Cooper et al.
EPILEPSY RESEARCH (2016)
Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome
A. Brunklaus et al.
BRAIN (2012)
Dravet syndrome: The long-term outcome
Pierre Genton et al.
EPILEPSIA (2011)
Share Paper
